论文部分内容阅读
巴塞达消息:在3,806例有原发性高胆固醇血症的中年男子参加的降低脂肪试验中,受试者将继续接受随访,以确定是否与使用消胆胺有关的癌发病率增加。迄今,研究结果一直良好。接受研究的男子参加了脂质研究医院冠脉初级预防试验,并进行过7—10年(平均7.4年)的随访。随机分为低胆固醇饮食加消胆胺组;另一组为,相同饮食加安慰剂。俄克拉何马医学研究基金会,脂质研究医院主任Reagan H Bradford说,两组病人的癌死亡率毫无差异。但癌的发生部位稍有不同。
BARTAIDA: In 3,806 middle-aged men with primary hypercholesterolemia, participants will continue their follow-up study to determine whether there is an increased incidence of cancer associated with the use of cholestyramine. So far, the results have been good. The men who took the study participated in the Primary Coronary Prevention Trial at the Lipid Research Hospital and were followed up for 7 to 10 years (an average of 7.4 years). Randomly divided into low cholesterol diet plus cholestyramine group; the other group, the same diet plus placebo. Reagan H Bradford, director of the Lipid Research Hospital at the Oklahoma Medical Research Foundation, said there was no difference in cancer mortality between the two groups. However, the site of cancer is slightly different.